Financial Performance - Amarin Corporation plc reported a year-end 2025 cash balance of $303 million, reflecting a growth of $16 million compared to $287 million in Q3 2025 [3] - The company expects its fiscal Q4 2025 net revenue to be in the range of $48 to $53 million, with fiscal year 2025 net revenue projected to be between $212 to $217 million [3] Operational Highlights - The company achieved positive cash flow in fiscal Q4 2025 earlier than previously forecasted, driven by a significant reduction in operating expenses and a long-term partnership with Recordati S.p.A. to commercialize VAZKEPA® across 59 countries, focusing on Europe [1] - Amarin believes it is on track for sustainable positive annual cash flow in 2026, supported by a full year of cost savings from its restructuring plan, with most expenses related to the plan already incurred in 2025 [2] Company Overview - Amarin Corporation plc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting cardiovascular health, specifically developing and commercializing Vascepa capsules [4]

Financial Performance - Total revenue for Q1 2025 was $42.0 million[14, 21] - U S revenue was $35.7 million, a ~26% year-over-year reduction[21] - Europe revenue was $5.4 million, a ~284% year-over-year increase[14, 21] - Operating expenses for Q1 2025 were $41.9 million, an 8% reduction year-over-year[14, 19] - The company maintained a strong cash position with $281.8 million and no debt[14, 24] Business Updates - Achieved sequential growth in in-market demand across all European markets where VAZKEPA was launched, particularly in Spain, the UK, and CEE[13] - Secured pricing and reimbursement in Austria and continued progress in other EU markets[13] - CSL's efforts led to VAZKEPA's inclusion in the National Heart Foundation/Cardiac Society Acute Coronary Syndrome guidelines in Australia[13] - Edding continued CVRR launch in the private pay market in China, working towards National Reimbursement Drug List (NRDL) review for 2026[13] Strategic Priorities - Drive growth in access and revenue in Europe and Rest of World markets[30] - Drive efficient VASCEPA U S revenue generation[30] - Support research that reinforces VASCEPA science and therapeutic value[30] - Maintain fiscal and operational discipline while pursuing all avenues to maximize shareholder value[30]